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Abstract
Objective: Purkinje neuron dysfunction is associated with cerebellar ataxia. In
a mouse model of spinocerebellar ataxia type 1 (SCA1), reduced potassium
channel function contributes to altered membrane excitability resulting in
impaired Purkinje neuron spiking. We sought to determine the relationship
between altered membrane excitability and motor dysfunction in SCA1 mice.
Methods: Patch-clamp recordings in acute cerebellar slices and motor pheno-
type testing were used to identify pharmacologic agents which improve Purkinje
neuron physiology and motor performance in SCA1 mice. Additionally, we ret-
rospectively reviewed records of patients with SCA1 and other autosomal-domi-
nant SCAs with prominent Purkinje neuron involvement to determine whether
currently approved potassium channel activators were tolerated. Results: Acti-
vating calcium-activated and subthreshold-activated potassium channels
improved Purkinje neuron spiking impairment in SCA1 mice (P < 0.05). Addi-
tionally, dendritic hyperexcitability was improved by activating subthreshold-
activated potassium channels but not calcium-activated potassium channels
(P < 0.01). Improving spiking and dendritic hyperexcitability through a combi-
nation of chlorzoxazone and baclofen produced sustained improvements in
motor dysfunction in SCA1 mice (P < 0.01). Retrospective review of SCA
patient records suggests that co-treatment with chlorzoxazone and baclofen is
tolerated. Interpretation: Targeting both altered spiking and dendritic mem-
brane excitability is associated with sustained improvements in motor perfor-
mance in SCA1 mice, while targeting altered spiking alone produces only short-
term improvements in motor dysfunction. Potassium channel activators cur-
rently in clinical use are well tolerated and may provide benefit in SCA patients.
Future clinical trials with potassium channel activators are warranted in cerebel-
lar ataxia.
Introduction
Degenerative cerebellar ataxias are a group of disorders
with progressive changes in balance, speech, and gait,
often leading to wheelchair confinement. There is a need
for agents which improve motor dysfunction in cerebellar
ataxia, as there is currently no approved treatment for
these debilitating disorders. In mouse models, neuronal
dysfunction precedes neuronal loss and occurs with the
onset of motor dysfunction.1–4 In human autopsy mate-
rial, in addition to cell loss, morphologically abnormal
neurons are consistently present.5 This suggests that neu-
ronal dysfunction may be an important feature of cerebel-
lar ataxia. Defining this neuronal dysfunction represents
an outstanding target for treatment of motor dysfunction
in cerebellar ataxia.
Spinocerebellar ataxias (SCA) are a group of domi-
nantly inherited disorders affecting the cerebellum and
related pathways. The most common SCAs (SCA1, SCA2,
SCA3, and SCA6) result from glutamine-encoding repeat
expansions in the respective disease-causing genes.6 Cere-
bellar Purkinje neuron degeneration is particularly
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prominent in autopsy tissue from SCA1, SCA2, and SCA6
patients. In addition, recent studies have demonstrated
that Purkinje neuron function is altered at the onset of
motor impairment in mouse models of SCA1 and
SCA2.1,2,4 Coordinated activity of an assortment of ion
channels supports repetitive spiking in Purkinje neurons
even in the absence of synaptic input.7–9 In mouse models
of SCA1-3, a subset of Purkinje neurons exhibit a loss of
spontaneous spiking and a depolarized membrane poten-
tial early in disease, which is related to reduced function
of potassium channels.1–3 In addition, potassium channel
dysfunction contributes directly to dendritic hyperex-
citability in these neurons, which may disrupt dendritic
signal integration and contributes to neurodegeneration.10
Although these studies demonstrate a clear relationship
between altered Purkinje neuron physiology and motor
impairment, the exact role for altered spiking and
increased dendritic excitability in causing motor dysfunc-
tion is unclear.
Ion channels are becoming increasingly recognized as
outstanding targets for the treatment of cerebellar ataxia.
Many SCAs are caused by conventional mutations in
ion channel genes (KCNMA1, KCNC3, KCND3, CAC-
NA1A, CACNA1G, ITPR1, SCA8A, TRPC3),6,11–18 and
alterations in ion channel function are secondary to dis-
ease-causing mutations in several mouse models of
spinocerebellar ataxia (SCA1, SCA2, SCA3, SCA6).1–4,19
In mouse models of SCA, ion channel modulators cor-
rect irregular Purkinje neuron spiking and improve
motor impairment.19,20 Recently, clinical trials for the
compound riluzole have demonstrated therapeutic pro-
mise for the treatment of several forms of SCA.21,22 The
known targets of riluzole include calcium-activated
potassium channels, some subthreshold-activated potas-
sium channels, and voltage-gated sodium channels.23,24
It is important to determine which ion channel targets
are relevant for treating symptoms in order to identify
effective drugs with reduced potential for off-target
effects.
In this study, we identify potassium channel modula-
tors which improve Purkinje neuron spiking and den-
dritic hyperexcitability in SCA1 mice. Our studies
suggest that targeting abnormalities in Purkinje neuron
spiking alone may be an effective short-term therapeutic
strategy, but that only a strategy which improves both
spiking and dendritic hyperexcitability provides long-
term benefit of motor dysfunction in SCA1 mice. Potas-
sium channel modulators that are effective in improving
motor dysfunction in the mouse model, and are also
approved for human use, are tolerated by patients with
SCA, and may be effective in improving motor dysfunc-
tion in forms of ataxia with prominent Purkinje neuron
involvement.
Methods
Mice
All animal procedures were approved by the University of
Michigan Committee on the Use and Care of Animals,
and were conducted in accordance with the United States
Public Health Service’s Policy on Human Care and Use
of Laboratory Animals. Homozygous ATXN1[82Q] trans-
genic mice,25 which overexpress human ATXN1 with 82
CAG repeats selectively in cerebellar Purkinje neurons
under the Pcp2 promotor, were maintained on an FVB
background. Wild-type FVB mice (Jackson Labs) were
used as controls for all experiments. All data presented
from these experiments were from mice at either 5 weeks
of age or 14 weeks of age. Sexes were balanced for all ani-
mal studies. For studies involving animals, an uppercase
“N” denotes the number of mice used per group, while a
lowercase “n” denotes the number of cells used per
group.
Patch-clamp electrophysiology: solutions
Artificial CSF (aCSF) contained the following (in mmol/
L): 125 NaCl, 3.8 KCl, 26 NaHCO3, 1.25 NaH2PO4, 2
CaCl2, 1 MgCl2, 10 glucose. For sections made at 4°C,
cutting solution contained the following (in mmol/L): 87
NaCl, 2.5 KCl, 25 NaHCO3, 1 NaH2PO4, 0.5 CaCl2, 7
MgCl2, 75 sucrose, 10 glucose. Unless otherwise specified,
pipettes were filled with an internal recording solution
containing the following (in mmol/L): 119 K Gluconate,
2 Na gluconate, 6 NaCl, 2 MgCl2, 0.9 EGTA, 10 HEPES,
14 Tris-phosphocreatine, 4 MgATP, 0.3 tris-GTP, pH 7.3,
osmolarity 290 mOsm. Proper calcium buffering is
important in order to support proper calcium-activated
potassium channel function. The EGTA concentration
was chosen based on previous studies which indicate that
0.5–1.0 mmol/L EGTA maintains Purkinje neuron cal-
cium-activated potassium channel function similar to
endogenous calcium buffering.1–3,26–30 In order to block
potassium channels in some dendritic excitability experi-
ments, pipettes were filled with an internal recording
solution containing the following (in mmol/L): 140 CsCl,
2 MgCl2, 1 CaCl2, 10 EGTA, 10 HEPES, 4 Na2ATP, pH
7.3, osmolarity 287 mOsm.
Patch-clamp electrophysiology: reagents
Baclofen (Sigma Aldrich, Saint Louis, MO, USA, Cat. No.
B5399) was used at 10 lmol/L for studies involving
somatic spiking, and at 2 lmol/L for experiments assess-
ing dendritic excitability. Chlorzoxazone (Sigma Aldrich,
Cat. No. C4397) was used at 50 lmol/L for all in vitro
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experiments. SKA-31 was synthesized in-house and was
used at 10 lmol/L for all in vitro experiments. 1-EBIO
(Tocris, Minneapolis, MN, USA, Cat. No 1041) was used
at 100 lmol/L for all experiments. Barium chloride
(Sigma Aldrich, Cat. No. 217565) was used at 50 lmol/L
or 500 lmol/L to block subthreshold-activated potassium
channels. Cadmium chloride (Sigma Aldrich, Cat. No.
C3141) was used at 100 lmol/L to block voltage-gated
calcium channels. Tetrodotoxin (Alomone Labs, Jerusa-
lem, Israel, Cat. No. T-550) was used at 1 lmol/L. During
some assessments of dendritic excitability, U-73122
(Tocris, Cat. No. 1268) was added to the internal pipette
solution at a concentration of 10 lmol/L to inhibit phos-
pholipase C.
Acute slice preparation for
electrophysiological recordings
Mice were anesthetized by isoflurane inhalation, decapi-
tated, and brains removed for slice preparation. For mea-
surements of somatic spiking and whole-cell somatic
physiology (Figs 1–3), slices were prepared in cutting
solution at 4°C as previously described.1–3,31,32 For den-
dritic calcium spike experiments, slices were prepared in
prewarmed (33°C) aCSF. Slice preparation at 33°C for
Purkinje neuron recordings has been performed previ-
ously33,34 and results in better preservation of dendritic
morphology in our studies. Slices were prepared using a
vibratome (Leica) to 300 lmol/L thickness. Slices were
incubated in 33°C aCSF bubbled with 5% CO2 and 95%
O2 (carbogen) for 45 min after sectioning.
Patch-clamp recordings
Patch-clamp recordings were performed as described pre-
viously.1 Cell-attached and whole-cell recordings were
performed at 33°C in carbogen-bubbled aCSF at a flow
rate of 2–3 mL/min 1–5 h after slice preparation. Record-
ings were performed using an Axopatch 200B amplifier,
Digidata 1440A interface, and pClamp-10 software (MDS
analytical technologies, Sunnyvale, CA). Data were
acquired at 100 kHz in the fast current-clamp mode of
the amplifier and filtered at 2 kHz. For some dendritic
excitability experiments, data were acquired using an
Axon Multiclamp 700B amplifier, with voltage data
acquired in current-clamp mode with bridge balance
compensation and filtered at 2 kHz. Cells were rejected if
the series resistance changed by more than 20% over the
duration of the recording, or if it exceeded 15 MO. Volt-
age traces were corrected for a 10 mV liquid junction
potential. For all recordings involving pharmacologic
agents, baseline data were acquired for 5 min before
introducing agents into the bath. Effects on spiking
persisted for the duration of the experiment, in some
cases more than 30 min.
Analysis of intrinsic dendritic excitability
Analysis of intrinsic dendritic excitability was performed
as described previously.35 Briefly, neurons were held at
80 mV in the whole-cell recording configuration in the
presence of tetrodotoxin (1 lmol/L) to block voltage-
gated sodium channels. Purkinje neuron somata were
then injected with depolarizing current in +50 pA incre-
ments until calcium spike events were noted. This
amount of injected current was used as a correlate of
dendritic excitability for all studies.
Phenotype analysis
Motor phenotype was analyzed by performance on a
rotarod. This study was powered to detect a 25%
improvement in motor performance, which was estimated
to require at least eight mice in each ATXN1[82Q] group.
In order to eliminate sampling bias, entire litters of mice
were randomly allocated to treatment groups used for all
behavioral experiments. Since litter size is variable, this
sometimes resulted in an unequal number of animals
used in each experimental group, but all ATXN1[82Q]
groups included at least eight mice. For all experiments,
mice were handled for three consecutive days starting at
25 days of age in order to acclimate to the experimenter
and test environment. Mice were then trained on an
accelerating rotarod (4–40 rpm, at a rate of 0.12 rpm/sec)
for 3 days followed by one training day at constant speed
(24 rpm). Baseline rotarod performance is variable
between individual cohorts of mice, so all experimental
groups were represented in each behavioral cohort.
Despite baseline differences in performance between
cohorts, we always observed impaired motor performance
in ATXN1[82Q] mice compared to wild-type controls. In
spite of controlling for testing time of day and experi-
menter, inherent biological variability in motor perfor-
mance exists within both ATXN1[82Q] and wild-type
mice. For this reason, all conditions for each experiment
were included during each run of an experiment. It is
therefore misleading to directly compare performance of
either ATXN1[82Q] or wild-type mice across different
experimental groups. Because of this inherent variability,
mice were randomized into groups based on their base-
line performance on the final day of training, and all
groups were balanced by sex and mean group perfor-
mance in order to establish a standard baseline within
each behavior cohort. Drug or vehicle was then adminis-
tered via water bottles for the duration of the experiment
after the final day of training. Mice were tested for 4 or
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5 days at a constant speed (24 rpm) starting at 35 days of
age for the early time point, and most groups were
retested at 98 days (14 weeks) of age for the long-term
time point. Latency score was recorded as either the time
taken before the animal fell off the bar, or if an animal
made three full rotations on the rotating bar, to a maxi-
mum time of 300 sec. Mice were maintained with water
bottle delivery of drug for the duration of the behavioral
experiment. After testing at the late time point, mice were
sacrificed and brains preserved for analysis of drug con-
centrations. The tester remained blind to genotype and
treatment condition during experimentation. Performance
on the rotarod was analyzed with a two-way repeated-
measures ANOVA by trial with Holm–Sidak multiple
comparison test.
Water bottle delivery of pharmacologic
agents
Baclofen was dissolved in drinking water at 350 lmol/L
for all studies. SKA-31 was dissolved in drinking water at
600 lmol/L for all studies. Since SKA-31 is not easily
water-soluble, drinking water also contained 0.05% b-
(hydroxypropyl)-cyclodextrin and 40 lL/L of 1N NaOH,
Figure 1. ATXN1[82Q] Purkinje neurons display both an absence of repetitive spiking and dendritic hyperexcitability. (A) Representative spiking of
a wild-type Purkinje neuron in the cell-attached recording configuration. (B) Representative trace of a nonspiking ATXN1[82Q] Purkinje neuron in
the cell-attached recording configuration. (C) Summary of spiking and nonspiking Purkinje neurons from wild-type and ATXN1[82Q] mice. (D)
Representative trace of a nonfiring ATXN1[82Q] Purkinje neuron in the whole-cell recording configuration. These neurons display a depolarized
resting membrane potential. (E) After-hyperpolarization (AHP) amplitude in wild-type and ATXN1[82Q] Purkinje neurons. (F) Summary of AHP
amplitudes in wild-type and ATXN1[82Q] Purkinje neurons. (G) Representative trace of a wild-type Purkinje neuron held at 80 mV in the
presence of tetrodotoxin. Upon injection of positive current in +50 pA increments, dendritic calcium spikes are noted. (H) Representative trace of
dendritic calcium spike analysis from an ATXN1[82Q] Purkinje neuron. (I) Summary of the threshold of injected current required to elicit dendritic
calcium spikes in wild-type and ATXN1[82Q] Purkinje neurons in the presence of tetrodotoxin. **P < 0.01, ***P < 0.001, Fisher’s exact test (C) or
two-sample Student’s t-test (I).
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and supplemented with up to 8% sucrose. Chlorzoxazone
was dissolved in drinking water at 15 mmol/L as
described previously.36 Similar to SKA-31, drinking water
containing chlorzoxazone also contained 0.05%
b-(hydroxypropyl)-cyclodextrin and 40 lL/L of 1 N
NaOH, and supplemented with up to 8% sucrose. For
vehicle treatment, drinking water containing 0.05% b-
(hydroxypropyl)-cyclodextrin, NaOH, and sucrose was
used. Water bottles were changed twice weekly. Mice
were treated with water bottles beginning at 28 days of
age and maintained on water bottles for the duration of
the experiment.
Mass spectrometry of brain tissue and
blood plasma
LC/MS analysis for SKA-31, chlorzoxazone, and baclo-
fen was performed with a Waters Acquity UPLC
Figure 2. Potassium channel-activating compounds restore spiking in nonfiring ATXN1[82Q] Purkinje neurons. (A) In a cell-attached recording
configuration, the majority of ATXN1[82Q] Purkinje neurons are nonfiring at 5 weeks of age. (B) Co-application of chlorzoxazone (CHZ, 50 lmol/
L) and baclofen (10 lmol/L) restores repetitive spiking to nonfiring ATXN1[82Q] Purkinje neurons (P = 0.001). Inset of restored spiking with
chlorzoxazone and baclofen is shown on an expanded time scale. (C) SKA-31 (10 lmol/L) and baclofen (10 lmol/L) co-application also restores
spiking to nonfiring ATXN1[82Q] Purkinje neurons (P = 0.01), as does (D) 1-EBIO (100 lmol/L) and baclofen (10 lmol/L) (P = 0.009). (E) Summary
of data from figures B–D. *adjusted P < 0.01 when compared to sham, Fisher’s exact test with Bonferroni postcorrection.
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(Waters, NY) interfaced to a TSQ Quantum Access
Max mass spectrometer (MS) (Thermo Scientific, Wal-
tham, MA).
SKA-31
Commercial SPE cartridges (Hypersep C18, 100 mg,
1 mL, Thermo Scientific) were conditioned with acetoni-
trile, 2 9 1 mL, followed by water 2 9 1 mL. After load-
ing the SPE cartridges with plasma samples, they were
washed with 2 mL of 20% acetonitrile in water and eluted
with 2 mL of acetonitrile. Elute fractions were evaporated
to dryness, reconstituted with 200 lL acetonitrile and
used for LC-MS analysis. For brain samples, 200 mg of
tissue were homogenized thoroughly in 4.0 mL of ace-
tonitrile using a T25 digital ULTRA-TURRAX homoge-
nizer (IKA Works Inc., NC), centrifuged for 10 min at
4000 rpm, and the supernatant separated and evaporated.
The residues were reconstituted in 200 lL acetonitrile
and loaded onto the preconditioned SPE cartridges and
then eluted as described above. Load and elute fractions
were collected and evaporated to dryness. The residues
were reconstituted with 200 lL acetonitrile and used for
LC-MS analysis on an Acquity UPLC BEH C-18 column
1.7 lmol/L, 2.1 9 50 mmol/L (Waters) using an isocratic
mobile phase (45% acetonitrile and 55% water containing
0.1% formic acid) with a flow rate of 0.25 ml/min. Under
these conditions, SKA-31 had a retention time of
1.17 min. Mass conditions: heated electrospray ionization
(HESI II) in positive ion mode, capillary temperature
350°C, vaporizer temperature: 325°C, spray voltage
4000 V, sheath gas pressure (N2) 30 units, SKA-31 was
analyzed by the selective reaction monitoring (SRM) tran-
sition of its molecular ion peak 201.04 (M + 1) into
115.16 m/z.
Baclofen
Baclofen was extracted by plasma precipitation; 1.0 mL
ethanol was added to 200 lL plasma and the resulting
precipitate vortexed for 30 sec. Samples were then cen-
trifuged for 5 min at 2500g, the supernatant separated
and evaporated to dryness under a constant air flow. The
residues were reconstituted with 200 lL water:acetonitrile
(1:1) and used for LC-MS analysis. For brain samples,
200 mg of tissue were homogenized thoroughly in 4.0 mL
of acetonitrile using a T25 digital ULTRA-TURRAX
homogenizer, centrifuged for 10 min at 4000 rpm, and
the supernatant separated and evaporated. The residues
were reconstituted with 200 lL acetonitrile and used for
LC-MS analysis on an Acquity UPLC BEH C-8 column
1.7 lmol/L, 2.1 9 150 mmol/L (Waters) using an iso-
cratic mobile phase (10% acetonitrile and 90% water con-
taining 0.1% formic acid) with a flow rate of 0.20 mL/
min. Under these conditions, baclofen had a retention
time of 2.1 min. Mass conditions: Heated electrospray
ionization (HESI II) in positive ion mode, capillary tem-
perature 300°C, vaporizer temperature: 250°C, spray volt-
age 3000 V, sheath gas pressure (N2) 35 units, baclofen
was analyzed by the SRM transition of its molecular ion
peak 214.04 (M + 1) into 151.03 m/z.
Chlorzoxazone
Chlorzoxazone was extracted by plasma precipitation;
3.0 mL acetonitrile was added to 200 lL plasma,
diluted with 200 lL of water and the resulting precipi-
tate vortexed for 30 sec. Samples were then centrifuged
for 5 min at 4000 rpm, the supernatant separated and
evaporated to dryness. The residues were reconstituted
with 200 lL water:acetonitrile (1:1) and used for LC-
MS analysis. For brain samples, 200 mg of tissue were
homogenized thoroughly in 4.0 mL of acetonitrile using
a T25 digital ULTRA-TURRAX homogenizer, cen-
trifuged for 10 min at 4000 rpm, and the supernatant
separated and evaporated. The residues were reconsti-
tuted with 200 lL acetonitrile and used for LC-MS
analysis on a Acquity UPLC BEH C-18 column
1.7 lmol/L, 2.1 9 50 mmol/L (Waters) using mobile
phase gradient varying from of 5% acetonitrile and
95% water both containing 0.1% formic acid (0–
1.5 min.) to 30% acetonitrile and 70% water (1.51–
5.0 min.) and back to 5% acetonitrile and 95% water
(5.01–6.0 min.) with a flow rate of 0.20 mL/min. Under
these conditions, chlorzoxazone had a retention time of
2.7 min. Mass conditions: Heated electrospray ionization
Figure 3. KCa activators and baclofen enhance the AHP and repolarize the membrane potential of ATXN1[82Q] Purkinje neurons. (A) Baclofen
(10 lmol/L) hyperpolarizes the membrane potential of depolarized ATXN1[82Q] Purkinje neurons to from 41 mV to 52 mV. Tetrodotoxin
(1 lmol/L) and cadmium (100 lmol/L) repolarizes the membrane potential to 60 mV. (B) Protocol for analysis of the time to minimal mid-AHP
and maximal AHP amplitude. (C) Representative trace of the AHP of an ATXN1[82Q] Purkinje neuron before (black trace) and after (red trace)
SKA-31 perfusion (10 lmol/L). The time to slow AHP minimum is denoted by arrows. (D) Summary of data from panel C. SKA-31 extends the
duration of the AHP in ATXN1[82Q] Purkinje neurons (P = 0.042). (E) Representative trace which displays the interspike interval during
spontaneous firing of a baseline wild-type Purkinje neuron and (F) ATXN1[8Q] Purkinje neuron in the presence of chlorzoxazone (50 lmol/L) and
baclofen (10 lmol/L). (G) Single interspike intervals of baseline wild-type and (H) ATXN1[82Q] Purkinje neurons in the presence of chlorzoxazone
and baclofen. *P < 0.05, **P < 0.01, ***P < 0.001, paired Student’s t-test. CHZ, chlorzoxazone.
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(HESI II) in negative ion mode, capillary temperature
300°C, vaporizer temperature: 250°C, spray voltage
3000 V, sheath gas pressure (N2) 25 units, chlorzoxa-
zone was analyzed by the SRM transition of its molecu-
lar ion peak 167.99 (M-1) into 132.07 m/z.
Review of patient charts
Patients were selected from the University of Michigan
Ataxia Clinic. All patients seen between January 2014 and
December 2016 with a diagnosis of SCA1, SCA2, SCA6,
SCA7, SCA8, and SCA13, where prominent Purkinje neu-
ron involvement is noted at autopsy, and for whom fol-
low-up data were available as of December 2016, were
included in this analysis. Patient SARA scores were
obtained prior to beginning treatment with chlorzoxazone
and baclofen and were measured at all subsequent follow-
up visits. While patient SARA scores were recorded as
part of their clinical care, the primary intent of this retro-
spective review was to determine the tolerability of com-
bined baclofen and chlorzoxazone treatment. Clinical
drug information databases discourage combined treat-
ment with chlorzoxazone and baclofen.37 In addition, the
Beers Criteria of the American Geriatrics Society also dis-
courages treatment with chlorzoxazone.38 For patients
who were maintained on this combination, SARA scores
were charted at all follow-up visits and are reported until
December 2016, through which IRB approval was
granted. In order to look for signal for therapeutic bene-
fit, we identified the minimum SARA score relative to the
SARA score recorded prior to initiation of medications.
Over follow-up visits, some patients showed a reduction
in SARA score following which they had worsening symp-
toms, while other patients continued a decline in SARA
score across serial visits. The goal of reporting patient
SARA scores is to identify whether there is potential ben-
efit in order to justify future randomized controlled clini-
cal trials.
Approval for retrospective review of patient charts seen
through the University of Michigan Ataxia Clinic was
submitted to the Institutional Review Board (IRB) for
human subjects. The IRB reviewed the study application
and determined that it is exempt from ongoing IRB
review, per the federal exemption category: Exemption #4
of the 45 CFR 46.101.(b): Research involving the collec-
tion or study of existing data, documents, records, patho-
logical specimens, or diagnostic specimens, if these
sources are publicly available or if the information is
recorded by the investigator in such a manner that sub-
jects cannot be identified, directly or through identifiers
linked to the subjects. Approval was granted for review of
records through December 2016.
Statistical analysis
Statistical significance for electrophysiology data was
assessed by either unpaired Student’s t-test, paired Stu-
dent’s t-test, or Fisher’s exact test with Bonferroni post-
correction for multiple comparisons. For behavioral
studies, a two-way ANOVA with Holm–Sidak postcorrec-
tion for multiple comparisons was used. Data were con-
sidered significant if the adjusted P < 0.05. Data are
expressed as mean  standard error of the mean, unless
otherwise specified. Data were analyzed using SigmaPlot
(Systat Software, Inc.), GraphPad Prism (GraphPad Soft-
ware, Inc.), and Excel (Microsoft Corp.).
Results
Alterations in Purkinje neuron spiking have been demon-
strated previously in the ATXN1[82Q] mouse model of
SCA1.2 In order to confirm these findings, we performed
cell-attached electrophysiological recordings in acute cere-
bellar slices from Purkinje neurons from ATXN1[82Q]
and wild-type mice at 5 weeks of age (Fig 1A–B). As
demonstrated previously, we observed that a significant
portion of ATXN1[82Q] Purkinje neurons displayed an
absence of repetitive spiking when compared to wild-type
neurons, which uniformly displayed repetitive spiking
(Fig 1C; firing frequency 52.2  5.6 Hz, coefficient of
variation in spiking 0.112  0.008). In the whole-cell
recording configuration, these nonfiring cells showed a
depolarized membrane potential of 41 mV (Fig 1D),
similar to what was previously described.2 These alter-
ations in membrane excitability are associated with a
reduction in the amplitude of the after-hyperpolarization
(AHP) of the action potential (Fig 1E–F), which is gener-
ated by calcium-activated potassium channels.2,39,40 Since
loss of potassium channels is associated with increased
dendritic excitability,35 we also determined whether Purk-
inje neuron dendrites from ATXN1[82Q] mice were
hyperexcitable. Purkinje neurons were held in the whole-
cell recording configuration at 80 mV in the presence
of tetrodotoxin (TTX, 1 lmol/L) in order to block volt-
age-gated sodium channels, and were injected with incre-
mental steps of depolarizing current until dendritic
calcium spikes were detected. In response to depolarizing
current injection, ATXN1[82Q] Purkinje neurons dis-
played a lower threshold to evoke dendritic calcium
spikes, a correlate of increased dendritic excitability
(Fig 1G–I).35 Input resistance was not different between
wild-type and ATXN1[82Q] Purkinje neurons (data not
shown). Therefore, Purkinje neurons from ATXN1[82Q]
mice exhibit a phenotype of increased membrane
excitability resulting in both altered spiking and increased
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dendritic excitability in association with membrane depo-
larization and a reduction in the amplitude of the AHP.
Alterations in Purkinje neuron spiking in ATXN1[82Q]
mice are associated with reductions in expression and
function of large-conductance calcium-activated potas-
sium (BK) channels and subthreshold-activated potassium
channels at the onset of motor impairment.2 In order to
determine whether the alterations in physiology which
accompany these changes in channel function can be
improved pharmacologically, we performed a targeted
screen of potassium channel-activating compounds with
known roles in membrane repolarization or increasing
AHP amplitude. A combination of chlorzoxazone and
baclofen restored tonic spiking to nonfiring ATXN1[82Q]
Purkinje neurons in acute cerebellar slices (Fig 2B).
Chlorzoxazone is a known activator of calcium-activated
potassium (KCa) channels, both BK and the related small-
conductance calcium-activated potassium (SK) chan-
nel.36,41–43 Baclofen, a GABAB agonist, potentiates a sub-
threshold-activated potassium channel current in Purkinje
neurons likely mediated by G-protein-coupled inwardly
rectifying potassium (GIRK) channels.44 In order to con-
firm whether KCa channels are a target for restored spik-
ing in ATXN1[82Q] Purkinje neurons, we tested other
known activators of KCa channels in the presence of
baclofen to determine their ability to restore spiking.
Spiking was restored in ATXN1[82Q] Purkinje neurons
that displayed no spontaneous spiking when co-perfused
with SKA-31 (Fig 2C) or 1-EBIO (Fig 2D), two known
KCa channel activators,
45, 46 and baclofen (summarized in
Fig 2E). The firing frequency that was restored was, how-
ever, significantly lower than what is normally seen in
wild-type Purkinje neurons (Chlorzoxazone + baclofen,
7.25  3.21 Hz; SKA-31 + baclofen, 10.13  1.86 Hz; 1-
EBIO + baclofen, 2.86  0.54 Hz). Effects on spiking
persisted for the duration of the experiment, in some
cases more than 30 min (data not shown). Chlorzoxa-
zone, SKA-31, or baclofen alone were unable to consis-
tently restore spiking in nonfiring ATXN1[82Q] Purkinje
neurons (Fig 2E). This suggests that KCa and subthresh-
old-activated potassium channels must be targeted simul-
taneously in order to restore spiking in nonfiring ATXN1
[82Q] Purkinje neurons.
In order to determine the mechanism by which potas-
sium channel activators restore spiking, we examined
changes in membrane potential produced by these phar-
macological agents. In the whole-cell configuration of the
patch-clamp technique, baclofen (10 lmol/L) repolarized
the membrane potential of depolarized ATXN1[82Q]
Purkinje neurons from 41 mV to 52 mV (Fig 3A). As
shown previously,2 a combination of TTX and cadmium,
to respectively block voltage-gated sodium and calcium
channels, restored the normal resting membrane potential
of ATXN1[82Q] Purkinje neurons (Fig 3A). These results
suggest that subthreshold-activated potassium channels
contribute in part to the depolarized potential of ATXN1
[82Q] Purkinje neurons. The SK channel-activating com-
pound SKA-31 extended the duration of the AHP in
ATXN1[82Q] Purkinje neurons, suggesting that KCa-acti-
vating compounds (shown in Fig 2) likely act on the
AHP to support repetitive spiking (Fig 3C–D). The net
effect of baclofen and chlorzoxazone was to greatly
enhance repolarization during the interspike interval
(Fig 3E–H). However, the duration of the AHP is
extended in ATXN1[82Q] Purkinje neurons perfused with
chlorzoxazone and baclofen, consistent with the reduced
firing frequencies in cells whose spiking is restored (see
Fig 2B–E). This indicates that increasing the amplitude of
the AHP through activation of KCa channels, in addition
to membrane repolarization through activation of sub-
threshold-activated potassium channels, is required to
facilitate repetitive spiking in depolarized ATXN1[82Q]
Purkinje neurons.
Prior studies in BK channel mutant mice have demon-
strated alteration in Purkinje neuron spiking similar to
what we observe in ATXN1[82Q] mice.39 Both pharmaco-
logic and genetic models of BK channel dysfunction also
exhibit profound motor impairment referable to cerebellar
dysfunction.39,47,48 We therefore sought to determine
whether agents which restore spiking could improve
motor impairment in ATXN1[82Q] mice. In order to
confirm oral absorption of chlorzoxazone, SKA-31, and
baclofen, we performed mass spectrometry analysis of
whole brain and plasma samples following administration
of these agents through drinking water. All three agents
achieved significant brain and plasma levels (SKA-31 brain
1.83  1.30 lmol/L, SKA-31 plasma 39.39  8.05 nmol/L;
chlorzoxazone brain 4.80  1.72 lmol/L, chlorzoxazone
plasma 4.41  2.05 lmol/L; baclofen brain 377.35 
58.50 nmol/L, baclofen plasma 3.06  0.51 lmol/L) that
reached concentrations previously shown to be important
for engagement of their respective targets (Fig 4B–D),36,44,45
although the achieved dose of SKA-31 is lower than the
maximal concentration achieved through intraperitoneal
injection.45 These agents were therefore administered
through drinking water in order to explore the relationship
between their ability to improve Purkinje neuron physiol-
ogy in cerebellar slices and ameliorate motor dysfunction.
ATXN1[82Q] and age-matched wild-type control mice
were administered either chlorzoxazone (15 mmol/L in
drinking water) and baclofen (350 lmol/L in drinking
water) or SKA-31 (600 lmol/L in drinking water) and
baclofen (350 lmol/L in drinking water) at 5 weeks, at
the onset of motor dysfunction2,49 and tested for both
short- and long-term improvement in motor dysfunction.
After 1 week of treatment, SKA-31 and baclofen
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significantly improved motor performance in ATXN1
[82Q] mice when compared to vehicle-treated controls
(Fig 4E). Similarly, following 1 week of treatment with a
combination of chlorzoxazone and baclofen, there was a
significant improvement in motor performance in
ATXN1[82Q] mice (Fig 4F). These results suggest that at
a time point corresponding to the loss of spiking in
ATXN1[82Q] Purkinje neurons, agents which restore
spiking are able to improve motor dysfunction.
In prior studies, we have observed that spiking in
ATXN1[82Q] Purkinje neurons is restored due to homeo-
static remodeling associated with Purkinje neuron atro-
phy.2 In order to determine whether potassium channel
activators continue to provide benefit at a stage of disease
when there is significant Purkinje neuron atrophy, mice
were administered these compounds through drinking
water from 5 weeks of age until 14 weeks of age and
motor performance was tested. ATXN1[82Q] mice treated
with SKA-31 and baclofen displayed impaired motor
function at 14 weeks of age (Fig 4G), while ATXN1[82Q]
mice treated with chlorzoxazone and baclofen showed a
sustained improvement in motor performance (Fig 4H).
These data suggest that although SKA-31 and chlorzoxa-
zone, in combination with baclofen, have a similar role in
restoring spiking, chlorzoxazone but not SKA-31 engages
a different target which allows for maintained improve-
ment in motor dysfunction.
In recent work, we have demonstrated that dendritic
hyperexcitability begins at the onset of motor dysfunction
in ATXN1[82Q] Purkinje neurons and is persistently ele-
vated in spite of relative normalization of spiking in
atrophic ATXN1[82Q] Purkinje neurons.10 As illustrated
previously, ATXN1[82Q] Purkinje neurons required a
significantly lower amount of injected current to elicit
dendritically generated calcium spikes than wild-type neu-
rons (Fig 5A–B) with no change in input resistance
(Wild-type + TTX 35.1  4.4, ATXN1[82Q] + TTX
43.1  1.9, P = 0.154). Surprisingly, chlorzoxazone
(Fig 5E and G) but not SKA-31 (Fig 5D) significantly
increased the threshold of injected current necessary to eli-
cit dendritic calcium spikes in ATXN1[82Q] Purkinje neu-
rons. The combination of chlorzoxazone and baclofen
restored dendritic excitability to near wild-type levels
(Fig 5F), suggesting that this combination of compounds
improves both spiking and dendritic hyperexcitability in
ATXN1[82Q] Purkinje neurons. Chlorzoxazone, SKA-31,
and baclofen did not alter input resistance in these record-
ings (ATXN1[82Q] + TTX 51.4  5.3, ATXN1[82Q] +
TTX + Chlorzoxazone 49.0  5.3, P = 0.705; ATXN1
[82Q] + TTX 47.8  6.8, ATXN1[82Q] + TTX + SKA-31
50.8  9.4, P = 0.777; ATXN1[82Q] + TTX 46.4  4.3,
ATXN1[82Q] + TTX + Baclofen + Chlorzoxazone 48.2 
6.3, P = 0.590).
SKA-31 is a highly selective activator of SK2 and IK
channels.45 The targets of chlorzoxazone are, however,
largely unknown. We therefore sought to determine the
ion channel targets of chlorzoxazone’s effect on dendritic
excitability. Chlorzoxazone does not likely act through SK
channels in the dendrites, since SKA-31 had no effect on
dendritic excitability. When tested in the presence of bar-
ium (50 lmol/L), which at this dose selectively blocks
subthreshold-activated inwardly rectifying potassium (Kir)
channels,2,50–54 the effect of chlorzoxazone on reducing
dendritic excitability was prevented (Fig 5G) (input resis-
tance ATXN1[82Q] + TTX + Barium 47.8  6.8, ATXN1
[82Q] + TTX + Barium + Chlorzoxazone 57.1  3.8,
Figure 4. Chlorzoxazone and baclofen, but not SKA-31 and baclofen, sustains improvement in motor dysfunction in ATXN1[82Q] mice. (A) Drug
administration and behavioral testing paradigm. (B) Correlated brain and plasma levels of SKA-31 are seen after administration through drinking
water (R2 = 0.1337). (C) Correlated brain and plasma levels of chlorzoxazone are seen after administration through drinking water (R2 = 0.8904).
(D) Correlated brain and plasma levels of baclofen are present after administration through drinking water (R2 = 0.8591). (E) After 1 week of
treatment, SKA-31 + baclofen improves motor performance in ATXN1[82Q] mice (F(2, 113) = 15.76, P < 0.0001) (Wild-type + Vehicle vs. ATXN1
[82Q] + Vehicle P < 0.0001; Wild-type + Vehicle vs. ATXN1[82Q] + SKA-31 + Baclofen P < 0.0001; ATXN1[82Q] + Vehicle vs. ATXN1
[82Q] + SKA-31 + Baclofen P = 0.004). (F) After 1 week of treatment, chlorzoxazone + baclofen improves motor performance in ATXN1[82Q]
mice (F(3, 156) = 42.23, P < 0.0001) (Wild-type + Vehicle vs. Wild-type + Chlorzoxazone + Baclofen P = 0.9726; Wild-type + Vehicle vs. ATXN1
[82Q] + Vehicle P < 0.0001; Wild-type + Vehicle vs. ATXN1[82Q] + Chlorzoxazone + Baclofen P < 0.0001; Wild-type + Chlorzoxazone + Baclofen
vs. ATXN1[82Q] + Vehicle P < 0.0001; Wild-type + Chlorzoxazone + Baclofen vs. ATXN1[82Q] + Chlorzoxazone + Baclofen P < 0.0001; ATXN1
[82Q] + Vehicle vs. ATXN1[82Q] + Chlorzoxazone + Baclofen P = 0.0036). (G) After 10 weeks of treatment, mice treated with SKA-31+ baclofen
show worsened motor performance compared with vehicle-treated controls (F(2, 109) = 36.73, P < 0.0001) (Wild-type vs. ATXN1[82Q] + Vehicle
P = 0.0005; Wild-type vs. ATXN1[82Q] + SKA-31 + Baclofen P < 0.0001; ATXN1[82Q] + Vehicle vs. ATXN1[82Q] + SKA-31 + Baclofen
P = 0.0408). (H) After 10 weeks of treatment, ATXN1[82Q] mice treated with chlorzoxazone + baclofen display sustained improvement in motor
performance compared with vehicle-treated controls (F(3, 144) = 29.43, P < 0.0001) (Wild-type + Vehicle vs. Wild-type + Chlorzoxazone + Baclofen
P = 0.0292; Wild-type + Vehicle vs. ATXN1[82Q] + Vehicle P < 0.0001; Wild-type + Vehicle vs. ATXN1[82Q] + Chlorzoxazone + Baclofen
P = 0.0097; Wild-type + Chlorzoxazone + Baclofen vs. ATXN1[82Q] + Vehicle P < 0.0001; Wild-type + Chlorzoxazone + Baclofen vs. ATXN1[82Q]
+ Chlorzoxazone + Baclofen P < 0.0001; ATXN1[82Q] + Vehicle vs. ATXN1[82Q] + Chlorzoxazone + Baclofen P = 0.0029). *P < 0.05, ** P < 0.01,
two-way ANOVA with Holm–Sidak posttest. CHZ, chlorzoxazone.
ª 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 307
D. D. Bushart et al. K+ Channel Activators Treat Cerebellar Ataxia
P = 0.173). This suggests that chlorzoxazone likely acti-
vates Kir channels in the dendrites of ATXN1[82Q] Purk-
inje neurons to reduce dendritic hyperexcitability.
We also sought to determine the molecular target of
baclofen on dendritic excitability. Although baclofen is
known to activate G-protein coupled Kir channels (GIRK)
in Purkinje neurons, barium (500 lmol/L) did not pre-
vent the effect of baclofen in reducing the threshold to
elicit dendritic calcium spikes (Fig 5H) (input resistance
ATXN1[82Q] + TTX + Barium 45.9  5.5, ATXN1
[82Q] + TTX + Barium + Baclofen 48.9  5.7, P = 0.588),
suggesting that baclofen does not modulate dendritic
excitability through these channels in ATXN[82Q] Purkinje
neurons. Since baclofen may act downstream of metabotro-
pic glutamate receptor (mGluR) signaling,55 we sought to
determine whether the effect of baclofen is dependent on
Figure 5. Chlorzoxazone and baclofen reduce dendritic hyperexcitability in ATXN1[82Q] mice by activating subthreshold-activated potassium
channels. (A) Representative trace of dendritic calcium spikes from a wild-type Purkinje neuron, (B) ATXN1[82Q] Purkinje neuron at baseline, and
(C) the same ATXN1[82Q] Purkinje neuron treated with chlorzoxazone (50 lmol/L) and baclofen (2 lmol/L). (D) SKA-31 (10 lmol/L) does not
reduce dendritic hyperexcitability in ATXN1[82Q] Purkinje neurons (P = 0.376). (E) Chlorzoxazone (50 lmol/L) reduces dendritic hyperexcitability in
ATXN1[82Q] Purkinje neurons (P = 0.025). (F) Chlorzoxazone (50 lmol/L) and baclofen (2 lmol/L) coadministration further reduces dendritic
excitability in ATXN1[82Q] Purkinje neurons (P < 0.001). (G) Barium (50 lmol/L) occludes the effect of chlorzoxazone on dendritic excitability
(P = 0.778). (H) Barium (500 lmol/L, P = 0.012), U73122 (10 lmol/L in recording pipette, P = 0.014), and TEA (1 mmol/L, P = 0.009) do not
occlude the effect of baclofen on dendritic excitability, but cesium chloride (140 mmol/L in the recording pipette) does occlude the effect of
baclofen on dendritic excitability (P = 0.356) in ATXN1[82Q] Purkinje neurons. *P < 0.05, **P < 0.01, ***P < 0.001, paired Student’s t-test. CHZ,
chlorzoxazone.
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mGluR activation. U73122, a phospholipase C inhibitor,
did not prevent the effect of baclofen on dendritic excitabil-
ity (Fig 5H) (input resistance ATXN1[82Q] + TTX
41.4  9.1, ATXN1[82Q] + TTX + U73122 39.1  8.3,
P = 0.478), suggesting that the effect of baclofen does not
require mGluR activation in this context.56 Cesium, a nons-
elective potassium channel inhibitor, prevents the effect of
baclofen when included in the recording pipette, confirm-
ing that baclofen activates a potassium channel conductance
in ATXN1[82Q] Purkinje neurons (Fig 5H) (input resis-
tance ATXN1[82Q] + TTX + CsCl 78.3  8.0, ATXN1
[82Q] + TTX + CsCl + Baclofen 77.8  8.1, P = 0.931).
Tetraethlyammonium (TEA) does not block the effect of
baclofen (Fig 5H), excluding Kv3 and BK channels as a tar-
get (input resistance ATXN1[82Q] + TTX + TEA 30.9 
4.2, ATXN1[82Q] + TTX + TEA + Baclofen 31  2.9,
P = 0.971). Overall, these data suggest that baclofen acti-
vates a relatively barium-insensitive subthreshold-activated
potassium channel in ATXN1[82Q] Purkinje neuron den-
drites to reduce dendritic hyperexcitability.
Chlorzoxazone and baclofen are both FDA-approved
compounds to reduce muscle spasticity, and chlorzoxa-
zone has previously been demonstrated to reduce down-
beat nystagmus in patients with cerebellar ataxia.57 In
mouse models of SCA1, SCA2, and SCA6, ataxias which
all display prominent Purkinje neuron involvement,
potassium channel dysfunction is present.1,2,19 Since pyra-
midal signs are a feature of many SCAs, and some
patients with SCA6 can exhibit downbeat nystagmus,
patients seen through the University of Michigan Ataxia
Clinic with either pyramidal signs or downbeat nystagmus
were offered a trial of baclofen and chlorzoxazone. All
patients were interested in a trial of the medications.
Since the American Geriatrics Society discourages com-
bining muscle relaxants through the updated Beers crite-
ria, it is important to know whether the combination of
baclofen and chlorzoxazone is tolerated by patients with
ataxia. In order to determine whether the combination of
chlorzoxazone and baclofen is tolerated by SCA patients,
we reviewed medical records of patients with SCA1 and
other SCAs with prominent Purkinje neuron involvement
who were seen through the Ataxia Clinic. Patients were
started on one agent at a time and the dose was gradually
increased to a target dose of 10 mg TID for baclofen and
500 mg TID of chlorzoxazone. If patients could not toler-
ate 500 mg TID of chlorzoxazone, a lower dose of
250 mg TID was attempted. Patients for whom follow-up
information was present as of December 2016 are listed
in Table 1. Of 17 patients, four could not tolerate one of
either baclofen or chlorzoxazone due to side effects
(Table 1). The Scale for the Assessment and Rating of
Ataxia (SARA) is a validated clinical measure of ataxia,
with higher scores indicating more prominent ataxia.58
SARA scores were recorded for all patients prior to begin-
ning treatment and were assessed during subsequent vis-
its. The average interval between visits for patients in the
Ataxia Clinic is 6 months. Patients reported subjective
improvement in symptoms over time which was
Table 1. Summary of spinocerebellar ataxia (SCA) patients treated with baclofen and chlorzoxazone.
Genotype Repeat size Sex Age Dosage Other comments
SCA1 52 M 29 Baclofen 40 mg BID, Chlorzoxazone 750 mg BID
SCA1 54 M 39 Baclofen 10 mg TID, Chlorzoxazone 500 mg TID
SCA1 Not
documented
F 67 Chlorzoxazone 250 mg once daily Could not tolerate; Chlorzoxazone made
swallowing worse
SCA1 52 F 36 Baclofen 10 mg TID, Chlorzoxazone 500 mg TID Could not tolerate due to nausea
SCA1 52 F 29 Baclofen 20 mg BID, Chlorzoxazone 750 mg BID
SCA1 53 M 35 Baclofen 30 mg TID, Chlorzoxazone 500 mg TID
SCA1 43 F 62 Baclofen 10 mg TID, Chlorzoxazone 250 mg TID
SCA1 46 F 58 Baclofen 10 mg TID, Chlorzoxazone 250/500 mg
SCA2 38 M 50 Baclofen 20 mg TID, Chlorzoxazone 500 mg TID
SCA2 38 M 67 Baclofen 10 mg TID, Chlorzoxazone 500 mg TID
SCA2 43 M 24 Baclofen 20 mg TID, Chlorzoxazone 500 mg TID
SCA6 21 M 57 Baclofen 10 mg TID, Chlorzoxazone 500 mg TID
SCA6 22 M 65 Baclofen 10 mg BID, Chlorzoxazone 500 mg BID Substantial improvement in downbeat nystagmus
SCA8 1268 F 79 Chlorzoxazone 500 mg BID Could not tolerate due to worsened speech
SCA8 108 F 62 Baclofen 10 mg TID Could not tolerate; Baclofen caused weakness
SCA8 Not
documented
M 51 Baclofen 10 mg TID, Chlorzoxazone 500 mg TID Improvement in swallowing and speech due to
improvement in dystonia
SCA13 n/a F 56 Baclofen 20 mg TID, Chlorzoxazone 500 mg TID
Patient demographics and dosage information are indicated. Patient genotype, CAG repeat size, age, sex, treatment dosage, and comments are
also listed.
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corroborated by the reduction in SARA score for individ-
ual patients (Fig 6A). Patients reported improvement in
symptoms that was delayed by weeks, after achieving
maximum tolerated doses of medication. In order to
assess the maximum benefit, initial SARA scores were
compared to minimum SARA scores subsequent to initia-
tion of chlorzoxazone and baclofen. The SARA score
subsequent to initiation of chlorzoxazone and baclofen
was significantly lower than the score prior to initiating
medication (Fig 6B; SARA prior 10.31  4.22
[mean  standard deviation], SARA minimum
7.85  4.85). Overall, these results indicate that chlorzox-
azone and baclofen coadministration is tolerated and may
improve symptoms in forms of SCA with prominent cere-
bellar Purkinje neuron involvement.
Discussion
In this study, we demonstrate that Purkinje neuron mem-
brane excitability is altered in ATXN1[82Q] mice, and
that the resulting changes in physiology can be targeted
by potassium channel activators. We illustrate that target-
ing somatic spiking is only effective for short-term
improvements in motor function. Targeting both spiking
and dendritic hyperexcitability is associated with sustained
improvement in motor dysfunction. Finally, we illustrate
that patients with ataxia can tolerate coadministration of
baclofen and chlorzoxazone, and that this combination
may improve motor dysfunction.
Growing evidence suggests that potassium channel dys-
function may be a feature of many cerebellar ataxias. In
mouse models of SCA1, SCA2, and SCA3, alterations in
Purkinje neuron spiking are associated with changes in
potassium channel function due to either transcriptional
downregulation (SCA1 and SCA2)1, 2 or altered potassium
channel kinetics (SCA3).3 In this study, we illustrate that
these changes in potassium channel function in ATXN1
[82Q] mice may be targeted by potassium channel-activating
compounds. Our study is the first to illustrate that not only
do potassium channel-activating compounds improve
motor dysfunction in a mouse model of SCA1, but also show
therapeutic promise in human SCA. We also illustrate that
more than one potassium channel target must be engaged in
order to sustain improvements in motor dysfunction.
Previous studies have focused on restoring somatic
spiking as an approach to improve motor function in
mouse models of ataxia.2,19,20,49 In this study, we illustrate
that improving Purkinje neuron spiking indeed improves
motor performance in the short-term, an effect which has
been previously illustrated using KCa activators in a mouse
model of SCA2.20 Motor dysfunction is likely not
improved to wild-type levels, however, as these com-
pounds restore firing only with a greatly reduced firing
frequency. However, restoring Purkinje neuron spiking
alone is not sufficient to improve motor dysfunction in
the long term. We illustrate that in association with the
additional reduction in dendritic hyperexcitability, longer
term benefit can be sustained in a mouse model of SCA1.
Since the targets of chlorzoxazone are unknown, it is pos-
sible that other mechanisms in addition to reducing den-
dritic excitability may play a role in mediating the
behavioral improvement demonstrated by chlorzoxazone.
While KCa-activating compounds effectively modulate
Purkinje neuron spike frequency and regularity, our data
suggest that additional engagement of subthreshold-acti-
vated potassium channels may be necessary for the sus-
tained improvement of motor impairment in ataxia. We
illustrate that both baclofen and chlorzoxazone reduce
dendritic hyperexcitability in ATXN1[82Q] mice, while
SKA-31 does not. Significantly, in our study, improvement
Figure 6. Chlorzoxazone and baclofen coadministration is tolerated in spinocerebellar ataxia patients and improves symptoms. (A) SARA scores
were obtained for each patient prior to beginning treatment with chlorzoxazone and baclofen, and subsequent SARA scores were obtained at
follow-up visits. SARA scores are only displayed for patients who could tolerate treatment and had at least one follow-up visit. (B) SARA scores
are displayed prior to treatment and at the time point which showed a minimum SARA score after beginning treatment (P = 0.004). **P < 0.01,
paired Student’s t-test.
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in motor dysfunction was sustained by chlorzoxazone and
baclofen even at a time point in ATXN1[82Q] mice when
there is significant Purkinje neuron dendritic degenera-
tion. Baclofen and chlorzoxazone both appear to activate
different subthreshold-activated potassium channels to
reduce Purkinje neuron dendritic hyperexcitability.
Addressing intrinsic dendritic hyperexcitability is likely an
important aspect of altered physiology which must be
addressed in order to sustain benefit in the treatment of
SCA, consistent with the critical role that intrinsic den-
dritic excitability plays in regulating synaptic integration.59
It is important to note that we and others have demon-
strated that in association with dendritic degeneration,
ATXN1[82Q] Purkinje neurons display increased sub-
threshold-activated potassium channel currents2,60 that
affect spiking. Nevertheless, agents that reduce dendritic
excitability through targeting these or other subthreshold-
activated potassium channels are beneficial in maintaining
improvements in motor dysfunction at a stage of disease
associated with dendritic degeneration. It is therefore
important to consider whether sustained improvements in
behavioral dysfunction are achieved in a neurodegenera-
tive disorder where, depending on disease stage, therapeu-
tic targets may vary. These findings also highlight the
importance of considering not only the acute effects of
pharmacological agents on motor function, but also the
durable effects of these compounds. Long-term adminis-
tration of these compounds enabled the identification of a
role for dendritic hyperexcitability in motor impairment
in ATXN1[82Q] mice.
Our studies assess alterations in intrinsic Purkinje neu-
ron excitability which are associated with disrupted spik-
ing and dendritic hyperexcitability. Synaptic alterations,
specifically in metabotropic glutamate receptor (mGluR)
signaling, are associated with motor impairment in mouse
models of SCA1.55,61 In a lentivirus model of SCA1, direct
cerebellar application of baclofen produces short-term
improvements in motor performance.55 This was attributed
to the ability of baclofen to potentiate mGluR1 signaling.
In contrast, in association with dendritic degeneration, pro-
longed and increased mGluR1 responses are now described
in models of both SCA1 and SCA2.61,62 At a stage of disease
associated with significant dendritic degeneration, inhibit-
ing mGluR1 improves motor function in ATXN1[82Q]
mice.61 In our studies, although baclofen’s ability to reduce
dendritic hyperexcitability appears to be independent of
mGluR signaling, the impairment of motor function upon
long-term treatment with baclofen and SKA-31 may repre-
sent baclofen-mediated activation of mGluR1 that is detri-
mental to Purkinje neuron physiology. It may therefore be
important to target dendritic subthreshold-activated potas-
sium channels without engaging mGluR signaling. Also, the
combination of baclofen and chlorzoxazone in patients is
dose limited due to sedation. Not all patients were able to
tolerate the target dose of the combination. It is therefore
important to consider developing subthreshold-activated
potassium channel activators, which can ideally also engage
KCa channels, possibly using chlorzoxazone as a template.
Centrally acting muscle relaxants, such as baclofen and
chlorzoxazone, have tolerability concerns in patients with
neurological disorders and older adults.37,38 It is therefore
important to consider whether these compounds are
appropriate for the treatment of SCA patients. In this
patient population, where motor impairment is promi-
nent, we found that baclofen and chlorzoxazone were tol-
erated in the majority of patients, and these patients
persisted in using these drugs. This is an important find-
ing, and is encouraging for design of a future clinical trial
with these agents. Furthermore, treatment with a combi-
nation of chlorzoxazone and baclofen is not only toler-
ated by SCA patients but may also improve symptoms.
Retrospective review of patient records and unblinded
assessments in patients are, however, susceptible to bias.
Given the duration of follow-up, and the sustained
improvements in patients where the natural history of
disease is progressive,63,64 our findings in patients are
encouraging for the utility of potassium channel activa-
tors in the treatment of symptoms in patients with SCA.
It is possible that changes in Purkinje neuron membrane
excitability are present in many etiologies of SCA, and that
the ion channel targets of chlorzoxazone and baclofen are
relevant targets in these SCAs as well. This possibility is
supported by recent clinical trials with the compound rilu-
zole, whose targets include KCa channels.
21,22 Although
riluzole shares common ion channel targets with chlorzoxa-
zone and baclofen, its effect on improving motor dys-
function is likely to be modest, as it has a relatively low
potency for both KCa channels and subthreshold-acti-
vated potassium channels.23,24 Compounds with
increased target specificity and potency are likely to be
more effective than riluzole. A clinical trial with a com-
bination of chlorzoxazone and baclofen should be con-
sidered for SCAs with prominent Purkinje neuron
involvement, as this combination of compounds targets
KCa channels with moderate potency and effectively tar-
gets subthreshold-activated potassium channels. While
chlorzoxazone and baclofen appear promising, agents
with added target specificity and potency could be
designed with these targets in mind.
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